Form 4 for FDMT 4D Molecular Therapeutics, Inc.
Accepted 2024-02-07 00:00:00 ET · period of report 2024-02-05 · accession 0000950170-24-012456 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2024-02-07 | 2024-02-05 | FDMT | Kim Robert Young | Chief Medical Off | M - OptEx | $15.29 | +24.0K | 7,595 | New | +$366.8K |
| DMT | 2024-02-07 | 2024-02-05 | FDMT | Kim Robert Young | Chief Medical Off | S - Sale+OE | $30.05 | -24.6K | 1,595 | -94% | -$737.8K |
| DMT | 2024-02-07 | 2024-02-05 | FDMT | Kim Robert Young | Chief Medical Off | M - OptEx | $0.00 | -24.0K | 64.0K | -27% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-05 | M | A | 12,000 | $18.66 | 13,595 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-05 | S | D | 12,000 | $30.05 | 1,595 | D | — | — | |
| 3 | Common | Common Stock | 2024-02-05 | M | A | 6,000 | $15.78 | 7,595 | D | — | — | |
| 4 | Common | Common Stock | 2024-02-05 | S | D | 552 | $30.05 | 1,043 | D | — | — | |
| 5 | Common | Common Stock | 2024-02-05 | M | A | 6,000 | $8.04 | 7,595 | D | — | — | |
| 6 | Common | Common Stock | 2024-02-05 | S | D | 6,000 | $30.05 | 1,595 | D | — | — | |
| 7 | Common | Common Stock | 2024-02-05 | S | D | 6,000 | $30.05 | 1,595 | D | — | — | |
| 8 | Derivative | Stock Option (Right to Buy) | 2024-02-05 | M | D | 6,000 | $0.00 | 54,000 | D | $8.04 · — to 2032-08-31 | 6,000 Common Stock | (F4) The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. |
| 9 | Derivative | Stock Option (Right to Buy) | 2024-02-05 | M | D | 12,000 | $0.00 | 138,000 | D | $18.66 · — to 2030-11-08 | 120,000 Common Stock | (F2) 25% of the shares subject to the option vest on the first anniversary measured from October 7, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest and become exercisable in equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. |
| 10 | Derivative | Stock Option (Right to Buy) | 2024-02-05 | M | D | 6,000 | $0.00 | 64,000 | D | $15.78 · — to 2032-01-31 | 6,000 Common Stock | (F3) The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. |